Clinical Trial Update: Intravitreal Bevacizumab and Low Fluence Photodynamic Therapy [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of intravitreal bevacizumab and low-fluence verteporfin photodynamic therapy for myopia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myopia

Drugs mentioned

• Avastin (bevacizumab)
• Visudyne (verteporfin)

Snippet

Sponsor: University of Campania Luigi Vanvitelli | Conditions: Myopia | Phase 1 | Status: COMPLETED